MARKHAM, ON, May 3, 2018 /CNW/ - MedReleaf Corp. ("MedReleaf" or the "Company") (TSX: LEAF) is aware of a recent news article speculating as to a potential transaction involving Aurora Cannabis. As a general policy, MedReleaf does not publicly comment on unusual market activity, rumors or speculation in the marketplace or any potential transaction unless, and until, a binding legal agreement to effect that transaction has been signed.

In response to a request by Investment Industry Regulatory Organization of Canada, the Company confirms that it engages from time to time in discussions with other industry players, including Aurora Cannabis, regarding various alternatives. The Company has not entered into an agreement to effect any particular transaction, and there can be no assurance that such discussions will result in any such agreement.

About MedReleaf Corp.

Voted Top Licensed Producer at the 2017 Lift Canadian Cannabis Awards, MedReleaf is an R&D-driven company dedicated to innovation, operational excellence and the production of top-quality cannabis. Sourced from around the world and carefully cultivated in one of two state of the art ICH-GMP and ISO 9001 certified facilities in Ontario, the Company delivers a variety of premium products for the global medical market and is committed to serving the therapeutic needs of its medical patients and providing a compelling product assortment for the adult-use recreational consumer. For more information on MedReleaf, its products, research and how the company is helping patients #livefree, please visit MedReleaf.com or follow @medreleaf.

Forward Looking Statements

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation, which can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "could", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information include estimates, plans, expectations, opinions, projections, targets, guidance or other statements that are not statements of fact. The forward-looking information contained in this press release are based upon MedReleaf's current internal expectations, estimates, projections, assumptions and beliefs and views of future events which management believes to be reasonable in the circumstances, including expectations and assumptions regarding the regulatory environment in Canada. Forward-looking information is subject to known and unknown risks and uncertainties, including risks and uncertainties which could cause actual events or results to differ materially from those described in any forward-looking information. Any forward-looking information contained herein speaks only as of the date on which it is given and, except as required by law, MedReleaf does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

SOURCE MedReleaf Corp.

For further information: Denise Riposati, Corporate Communications, [email protected], 289-317-1000 EXT 1118; Dennis Fong, Investor Relations, [email protected], 416-283-9930